anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Citalopram
Trial phase: Phase 4
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Citalopram: 20mg/day for the first 4 weeks, followed by the option to increase the dose to 40mg per day for the remainder of the study period.
Eligibility criteria:
Inclusion Criteria:

An OPCRIT (Operational Criteria Checklist for Psychosis: 57) diagnosis of schizophrenia, schizophreniform, schizoaffective disorder or psychosis NOS as defined by DSM-IV.
A negative subscale score of 20 or more on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS). At least three of the seven items on the negative symptom subscale should be rated 3 or more.
Age 18-75 years, inclusive
Clinically stable for the last 3 months with a consistent antipsychotic regimen.
Competent and willing to provide written, informed consent.

Exclusion criteria:

Any medical contraindications to an SSRI antidepressant.
Currently receiving antidepressant or clinician wants to treat with an antidepressant;
Taking any medications that risk interacting with citalopram
Known congenital long QT syndrome, congestive heart failure, bradyarrhythmias
QT limit above the upper limit of normal as determined by an electrocardiogram (ECG)
Serum potassium and/or magnesium levels below the lower limits of normal
Currently fulfil criteria for major depressive disorder; alcohol/substance hazardous use or dependence in past 3 months
Treated with ECT in the last 8 weeks.
Pregnant or planning to become pregnant
Cognitive or language difficulties that would preclude subjects providing informed consent or compromise participation in study procedures.
Lack of consent, as judged by the patient's psychiatrist
Intervention: Memantine
Trial phase: Phase 4
ATC code: N06DA52 | N06DA53 | N06DX01
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Memantine: 20 mg, BID
Eligibility criteria:
Inclusion Criteria:

Male
Age 18 to 75 years old

Exclusion Criteria:

Chronic pain conditions or taking regular analgesics
Taking psychotropic medications
Parkinson's disease
Narrow-angle glaucoma
Known gastroduodenal ulcer
History of seizure disorder
Renal insufficiency, as defined by serum creatinine greater than 2 mg/dL
Liver disease, including liver failure, cirrhosis, or acute hepatitis
Significant coronary vascular disease or cardiac conduction system disease, as noted by ECG or history of cardiac symptoms, or cardiac ejection fraction less than 30%
American Society of Anesthesiologists (ASA) score of 4 or higher
Allergy to ketorolac or memantine
Intervention: Olmetec Plus
Trial phase: Phase 3
SMILES: CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1.NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 364
Group description: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.

Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.

Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg.
Females of childbearing potential who are sexually active agree to routinely use adequate contraception from Screening through 30 days after the last administered study drug dose.
Has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant.
Is willing to discontinue current antihypertensive medications on Day -21 or Day -28 if the participant is on amlodipine or chlorthalidone.

Exclusion Criteria:

Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg on Day -1.
Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficient quality.
Works a night (third) shift.
Has an upper arm circumference less than 24 cm or greater than 42 cm.
Has secondary hypertension of any etiology.
Has a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
Has clinically significant cardiac conduction defects.
Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
Has severe renal dysfunction or disease.
Has known or suspected unilateral or bilateral renal artery stenosis.
Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
Has poorly-controlled diabetes mellitus at Screening.
Has hypokalemia or hyperkalemia.
Has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.
Has any other known serious disease or condition that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow the participant according to the protocol.
Has known hypersensitivity to angiotensin II receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds.
Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
Intervention: Sodium Nitrite
Trial phase: Phase 1 | Phase 2
ATC code: V03AB08
SMILES: O=N[O-].[Na+]
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Administration if sodium nitrite injection, USP

sodium nitrite injection, usp: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
Eligibility criteria:
Inclusion Criteria:

Subjects meeting all of the following criteria will be considered for admission to the study:

Male or female subject aged between 8 and 23 years of age; only patients up to the age of 23 will be studied at Childrens Hospital Los Angeles
Electrophoretic diagnosis of sickle cell disease;
Sudden onset of acute pain involving >=1 sites typical of vaso-occlusive crisis (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest, abdomen, or back that can not be explained by other complications of sickle cell disease or by a cause other than sickle cell disease.);
Severe pain requiring parenteral analgesics and hospitalization.
Informed consent obtained from a legal representative or from subjects 18 years of age or older before enrollment;
Being willing and able to be followed for at least 30 days for evaluation.

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

Clinically significant bleeding;
Current drug abuse or participation in methadone program;
Episode of pain requiring hospitalization within 2 weeks prior to current admission;
Other complications of sickle cell disease including cerebrovascular accident, pulmonary hypertension, or seizure;
Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding;
Blood pressure less than 25th percentile for the subject's age and sex on admission or at the time of screening;
Methemoglobinemia >3%;
Anemia with hemoglobin level less than 6 g/dL;
Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;
History of allergy to nitrites or allergy to other substances characterized by dyspnea and cyanosis;
Treatment with allopurinol, a medication that could interfere with nitrite metabolism, within the past 30 days before screening;
Treatment with any investigational drug within the past 30 days;
Significant acute or chronic concomitant diseases (including renal, hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 6 months;
Any subject judged by the clinical investigator or study manager to be inappropriate for the study.
Intervention: Panobinostat
Trial phase: Phase 3
ATC code: L01XH03 | L01XX42
SMILES: Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Participants received 45 mg orally 3 times a week (TIW), every other week (QOW).
Eligibility criteria:
Inclusion Criteria:

Patient age is greater than or equal to 18 years
Patient has a history of histologically confirmed classical HL (i.e. Nodular sclerosing (NSHL), Mixed-cellularity (MCHL), Lymphocyte-rich (LRHL), Lymphocyte depleted (LDHL))

Patient has achieved a complete response by CT/MRI scan within 9 weeks (± 1 week) from the day of their first autologous peripheral blood/ bone marrow stem cell transfusion (AHSCT) following HDT. Complete response is defined as:

Normalization of all nodes and lesions compared to pre-transplant scan performed prior to salvage therapy for relapse. Any residual abnormal masses on the post transplant CT/MRI must be metabolically inactive on a PET scan.

Patient has at least one of the following factors that places them at risk for relapse:

Primary refractory disease (including relapse in ≤ 3 months of completion of 1st line treatment)
First relapse >3 but <12 months from last dose of 1st line treatment
Multiple relapses (prior to transplant)
Stage III/IV disease (at relapse, prior to transplant)
Hemoglobin <10.5 gm/dL (at relapse, prior to transplant)

Exclusion Criteria:

Patient has been treated with allogeneic transplant 2. Patient has received any anti-lymphoma therapy after AHSCT including but not limited to:

chemotherapy prior to start of study
biologic immunotherapy including monoclonal antibodies or experimental therapy prior to start of study
radiation therapy 3. Patient has not recovered from reversible toxicity due to any prior therapies (e.g. returned to baseline or Grade ≤1) except for hematological laboratory parameters Note: Patient does not meet this criteria if the toxicity is stable and irreversible, and there is no evidence that panobinostat causes a similar toxicity 4. Patient has received prior treatment with DAC inhibitors including panobinostat
Intervention: Ofloxacin
Trial phase: Phase 4
ATC code: A02BD10 | J01MA01 | J01MA12 | J01RA05 | J01RA09 | S01AE01 | S01AE05 | S02AA16
SMILES: CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days

levofloxacin: 500 mg tablet, daily, 30 days
Eligibility criteria:
Inclusion Criteria:

Living and cadaveric kidney transplant recipients over the age of 18 years with BK viremia

Exclusion Criteria:

Female patients of childbearing age who are pregnant or in whom adequate contraception cannot be maintained.
Patients with active infections, history of malignancy/Posttransplant Lymphoproliferative Disease (PTLD) serologic positivity to HIV.
Patients with evidence of urinary tract obstruction causing allograft dysfunction, unless corrected by time of enrollment.
Patients with clinical or morphological evidence of recurrence of primary disease.
Patients with a history of allergic reaction to quinolone antibiotics.
Patients with history of prolong QT interval
Patients with recurrent hypoglycemic episodes
Patients with history of myasthenia gravis
Patients taking Thioridazine
Intervention: Lovaza
Trial phase: Not Applicable
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Data from the 2 treatment sequences (POM3/control and control/POM3) were pooled.
Eligibility criteria:
Inclusion Criteria:

Men and postmenopausal women, ages 18-79 years.
Fasting, triglyceride (TG) level in the borderline high to high range.
Fasting, low density lipoprotein cholesterol (LDL-C) below the very high range while on no lipid altering therapy or while taking stable-dose statin therapy
Provide written informed consent and authorization for protected health information

Exclusion Criteria:

Use of any lipid-altering medications, which cannot be stopped, except stable dose statin therapy.
Use of any omega-3 fatty acid ethyl ester medications or dietary supplements with >1.0 g/d of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or a combination of EPA and DHA
coronary heart disease (CHD) or a CHD risk equivalent
Body mass index over 45 kg per square meter
Allergy or sensitivity to omega-3 fatty acids, corn or corn products (e.g., corn oil), D-alpha tocopherol (vitamin E) or any ingredients in the study drug
Certain muscle, liver, kidney, lung or gastrointestinal conditions
Poorly controlled hypertension
Certain medications
Active cancers treated within prior 2 years (except non-melanoma skin cancer)
Intervention: Duloxetine
Trial phase: Phase 4
ATC code: N06AX21
SMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Duloxetine: 30-60 mg daily for 8 weeks
Eligibility criteria:
Inclusion Criteria:

> 17 years old
All races and ethnicity
DSM IV-TR Axis I diagnosis of MDD
Co-morbid STDS
Baseline 17-item Hamilton Depression Rating > 13

Exclusion Criteria:

Primary Axis I disorder other than MDD
History of mania or psychosis
Actively suicidal
Required hospitalization
A alcohol or substance abuse or dependence within the preceding 3 months
Pregnant or nursing
Unstable medical condition (other than STDS)
Narrow-angle glaucoma
Sensitivity to duloxetine, concurrent antidepressant, tranquilizer, or mood stabilizer use
Hepatic or renal insufficiency
Intervention: Orlistat
Trial phase: Phase 4
ATC code: A08AB01
SMILES: CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Patients assigned to treatment group for up to 6 months of therapy.
Eligibility criteria:
Inclusion Criteria:

adult patients preparing for gastric bypass surgery

Exclusion Criteria:

pregnancy
Intervention: Warfarin
Trial phase: Phase 2
ATC code: B01AA03
SMILES: CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
Eligibility criteria:
Inclusion Criteria:

At least 16 years of age
Have a confirmed diagnosis of sickle cell anemia (HbSS) or sickle cell beta zero thalassemia
Have evidence of persistent elevation of pulmonary artery systolic pressure on Doppler echocardiography (TR jet velocity of 2.5 to 2.9 m/s [or estimated pulmonary artery systolic pressure above the upper limit of reference adjusted ranges and up to 45 mm Hg]), but no evidence of moderate or severe diastolic dysfunction on tissue Doppler echocardiography. Mild PHT must be confirmed on repeat evaluation, at least 3 months later
Have a serum creatinine =/< 1.5 mg/dl
Have serum transaminase values (ALT) < 2 times upper limits of normal
Have serum albumin =/> 3.2 g/dl
Have a platelet count =/< 150,000 cu/mm
Have normal baseline coagulation profile (PT/PTT)
Patients on treatment with hydroxyurea should be on a stable dose for at least 6 months. Doses of hydroxyurea may only be adjusted during the course of the study for safety reasons.
Be able to understand the requirements of the study and be willing to give informed consent.
Women of childbearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception.

Exclusion Criteria:

Have a baseline hemoglobin < 6.0 gm/dl
Have congenital heart disease, valvular heart disease, and other identified cause of pulmonary hypertension (including pulmonary fibrosis) unrelated to SCD
Have an elevated pulmonary capillary wedge pressure, as evidenced by E/Em > 15 by pulsed wave and tissue Doppler imaging
Have no measurable tricuspid regurgitant velocity on echocardiography
Have a history of major gastrointestinal bleeding or a bleeding diathesis
Have sickle cell complications such as recent vaso-occlusive crisis or acute chest syndrome, 4-weeks prior to commencing the study
Have a history of clinically overt stroke(s) or seizures
Have a brain magnetic resonance imaging/magnetic resonance angiography scan with evidence of Moya Moya within the preceding year
Are pregnant or breastfeeding
Are on chronic anticoagulant therapy
Have a history of metastatic cancer
Are chronically on therapy with aspirin or non-steroidal anti-inflammatory agents
Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks
Have a positive urine toxicology screen for cocaine and amphetamines
Have a history of alcohol abuse
Are currently receiving treatment with epoprostenol (or similar prostacyclin analog), sildenafil (or similar phosphodiesterase 5 inhibitor), bosentan or arginine
Have ingested any investigational drugs within the past 4 weeks.
Intervention: Humulene
Trial phase: Phase 1 | Phase 2
SMILES: CC1=CCCC(C)=CCC(C)(C)C=CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: 0% 9-delta tetrahydrocannabinol by weight
Eligibility criteria:
Inclusion Criteria:

Age greater than 18 and less than 70
Visual Analogue Scale (VAS pain intensity) greater than 3/10
A negative urine drug screening test, i.e., no evidence of IV drug abuse
Neuropathic pain due to reflex sympathetic dystrophy, peripheral neuropathy, post-herpetic neuralgia, post-stroke pain, multiple sclerosis or spinal cord injury

Exclusion Criteria:

Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied.
Subjects with moderate-severe major depression, bipolar/mania, bipolar II/hypomania and schizophrenia or schizoaffective disorder.
Unstable Type 1 or 2 diabetes defined as blood glucose more than 156 mg/dl
History of traumatic brain injury
Uncontrolled medical condition, including coronary artery disease, hypertension, cerebrovascular disease, asthma, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), opportunistic infection, malignancy requiring active treatment, active substance abuse (alcohol or injection drugs).
Current use of marijuana (e.g., within 30 days of randomization)
Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test.
Intervention: Vancomycin
Trial phase: Not Applicable
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Subject receives vancomycin 30 mg/kg dose
Eligibility criteria:
Inclusion Criteria:

Age 19 to 70 years
Weight 40 - 80 kg
Suspected or confirmed skin or soft tissue infection for which vancomycin is indicated
Subject referred to or admitted into OPAT by an Infectious Disease Specialist or Emergency Physician
Subject able to provide informed consent

Exclusion Criteria:

Known history of allergy to vancomycin
Pregnancy
Granulocytopenia (< 1x109/L)
Renal impairment (serum creatinine > 177 µmol/L or eGFR < 50 mL/min)
Known history of vestibular disease or hearing loss
Subjects treated with vancomycin within the previous month
Subjects who have received more than 24 hours of vancomycin
Subjects receiving other antimicrobials that cover MRSA (e.g. cotrimoxazole, rifampin, linezolid)
Intervention: Vancomycin
Trial phase: Not Applicable
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Subject receives vancomycin 15 mg/kg twice daily
Eligibility criteria:
Inclusion Criteria:

Age 19 to 70 years
Weight 40 - 80 kg
Suspected or confirmed skin or soft tissue infection for which vancomycin is indicated
Subject referred to or admitted into OPAT by an Infectious Disease Specialist or Emergency Physician
Subject able to provide informed consent

Exclusion Criteria:

Known history of allergy to vancomycin
Pregnancy
Granulocytopenia (< 1x109/L)
Renal impairment (serum creatinine > 177 µmol/L or eGFR < 50 mL/min)
Known history of vestibular disease or hearing loss
Subjects treated with vancomycin within the previous month
Subjects who have received more than 24 hours of vancomycin
Subjects receiving other antimicrobials that cover MRSA (e.g. cotrimoxazole, rifampin, linezolid)
Intervention: Udenafil
Trial phase: Phase 3
ATC code: G01AE10 | G04BE11
SMILES: CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 155
Group description: Udenafil 50 mg tablets
Eligibility criteria:
Inclusion Criteria:

Male, at least 19 years of age
Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity
History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
Partner is not pregnant or lactating

Exclusion Criteria:

History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months
Cardiac arrhythmias requiring antiarrhythmic treatment
Symptomatic congestive heart failure
Taking nitrate medication in any form
Uncontrolled diabetes (HbA1c ≥ 13%)
Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®
Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®
Intervention: Udenafil
Trial phase: Phase 3
ATC code: G01AE10 | G04BE11
SMILES: CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 150
Group description: Udenafil 100 mg tablets
Eligibility criteria:
Inclusion Criteria:

Male, at least 19 years of age
Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity
History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
Partner is not pregnant or lactating

Exclusion Criteria:

History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months
Cardiac arrhythmias requiring antiarrhythmic treatment
Symptomatic congestive heart failure
Taking nitrate medication in any form
Uncontrolled diabetes (HbA1c ≥ 13%)
Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®
Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®